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Background: Bronchiectasis remains a signiﬁcant cause of morbidity among speciﬁc
populations world wide, including many indigenous groups. Data on prevalence in
Australian adults are lacking. Indigenous children in Central Australia have the highest
rates of bronchiectasis in the world. Outcomes for these individuals after they become
adults are not currently available.
Methods: We performed a retrospective case review of the presentation and likely
aetiology of adult patients presenting to the Alice Springs Hospital with a primary diagnosis
of bronchiectasis.
Results: Sixty-one patients and 166 admissions were identiﬁed. Fifty-nine patients were
indigenous (97%). Mean age was 42715 years. Forty-three patients (70%) had past histories
notable for recurrent respiratory tract infections. No predisposing factors could be
identiﬁed in 11 patients (18%). Human T-cell lymphotropic virus type 1 (HTLV-1) serology
was positive in 72% of those studied. Eight (13%) patients died during the study period.
Conclusion: Bronchiectasis remains a signiﬁcant cause of morbidity and mortality in
Central Australia, with notably different patient characteristics and disease aetiology to
other published cohorts. Recurrent respiratory infection is the major cause of illness.
Associated factors include indigenous ethnicity, HTLV-1 positivity and childhood in a
remote region.
& 2007 Published by Elsevier Ltd.Published by Elsevier Ltd.
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l).Introduction
Bronchiectasis is an anatomical diagnosis describing irrever-
sibly dilated bronchii, associated with bronchial wall
distortion, inﬂammation, and destruction. It was a common
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Table 1 Demographic data.
No. of patients 61
Male/female 32 (52%)/29 (48%)
Age at admission (yr7SD) 42715
Background
Indigenous 59 (97%)
Non-indigenous 2 (3%)
Location (childhood)
Remote 51 (84%)
Urban 3 (5%)
Unclear 7 (11%)
Location (current)
Remote 43 (70%)
Urban 18 (30%)
Bronchiectasis in Central Australia 575disease in the pre-antibiotic era although its prevalence is
felt to have fallen in developed countries1 following the
introduction of vaccination and antibiotics and the decline
in tuberculosis.2 Current data is lacking and speciﬁc
populations, particularly indigenous people of Alaska, the
South-west Paciﬁc, and South-east Asia continue to suffer
high rates of disease.3,4 Indigenous children living in Central
Australia have amongst the highest reported rates of
bronchiectasis in the world,5 though the consequences of
bronchiectasis for these individuals after they enter adult-
hood have not been studied.
Our experience suggested the Central Australian adult
population served by our hospital experience signiﬁcant
morbidity due to bronchiectasis and, moreover, that patient
features differ signiﬁcantly from cohorts representative of
urban populations. We therefore examined data from a large
cohort of patients presenting with bronchiectasis to Alice
Springs Hospital (Northern Territory, Australia) over a
12-month period.Methods
A retrospective review of all adult patients admitted to
Alice Springs Hospital between July 1, 2004 and June 30,
2005 was performed. Alice Springs Hospital is a 164 bed
facility and is the only hospital servicing the Central
Australia Region (approximately 1,000,000 square kilo-
metres). The area has a population of approximately
47,000 people, of whom 40% are indigenous.6 The closest
referral centres are Darwin and Adelaide, both over 1500
kilometres from Alice Springs.
All adult patients with a discharge diagnosis of bronch-
iectasis were identiﬁed by analysis of hospital admission
data for the study period. The diagnosis of bronchiectasis
was considered to be conﬁrmed if at any time during or prior
to the admission a patient with typical clinical features of
bronchiectasis demonstrated classic radiographic changes of
bronchiectasis on either chest X-ray (CXR) (tram-tracking,
ring shadows, cystic change) or high-resolution compu-
terised tomography (HRCT) of chest (airway dilatation,
bronchial wall thickening, cystic change). Patient histories
were then reviewed for clinical, microbial, spirometric, and
demographic data. All information recorded, including
microbial and laboratory results, were obtained in the
routine care of each patient with no subsequent investiga-
tions performed to aid our study.
Statistical analysis was performed using the Microsoft
Excel 2004 for Mac (Microsoft Corporation, Redmond, WA,
USA).
The project received approval from the Central Australian
Human Research Ethics Committee. The requirement of
informed consent for use of retrospective data was not
required by the committee.Results
During the study period, 69 patients were admitted to Alice
Springs Hospital with a primary diagnosis of bronchiectasis.
Eight patients had no radiographic evidence of bronchiec-
tasis on either CXR or HRCT. The remaining 61 patients formthe basis of this report. Demographic data are recorded
in Table 1.
The initial diagnosis of bronchiectasis had been made by
CXR in 29 patients (47.5%), HRCT in 29 patients (47.5%), and
plain CT chest in three (5%). Eleven patients had not had CT
imaging of the chest at the time of our report. No patients
had undergone bronchoscopy or bronchography.
Twenty-seven patients (44%) were current smokers, 17
were non-smokers (28%), 10 were ex-smokers (16%), and
smoking status was not recorded in seven (11%).
Eight patients died during the 12-month-study period.
Seven deaths were due to respiratory illness and one due to
complications of non-related trauma.Aetiology
Forty-three patients (70%) had past histories notable for
recurrent childhood respiratory infections. Three patients,
one indigenous and two non-indigenous, had severe chronic
obstructive pulmonary disease (COPD) with bronchiectasis
noted on HRCT. One patient had respiratory syncitial virus
pneumonia documented in infancy. A further patient had
severe Nocardia pneumonia requiring intubation and tra-
cheostomy. Bronchiectatic changes were correlated with the
distribution of consolidation seen during their pneumonic
illness. Two patients had conditions predisposing to recur-
rent aspiration (Down’s syndrome, severe intellectual
disability). No predisposing factors were identiﬁed in 11
patients. Factors identiﬁed in the development of bronch-
iectasis are summarised in Table 2.
Relatively, few patients had investigation for underlying
disorders. Six patients were tested for a1-antitrypsin
deﬁciency; all were normal. Immune investigations included
anti-nuclear antibodies in seven, with two positive, at low
titres. In the absence of other rheumatic symptoms this
was thought to be due to acute infection. Serum protein
electrophoresis and immunoglobulin levels were normal in
all six patients studied. Rheumatoid factor was negative in
all seven patients studied. Aspergillus precipitans were
negative in three patients, though serum immunoglobulin E
was noted at41000 ng/mL in one patient. A. fumigatus was
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Table 2 Aetiology of bronchiectasis.
Number Nicotra
et al.8 (%)
Recurrent respiratory
infection
43 (70%) NS
Bronchiectasis secondary
to COPD
3 (5%) 0
Severe acute respiratory
infection
2 (3%) 35
Micro-aspiration 2 (3%) NA
Pertussis 0 (0%) 7.3
Granulomatous disease 0 (0%) 9.8
Genetic disease 0 (0%) 4.1
No factors noted 11 (18%) 30
NS—not stated in published article.
Table 3 Microbiological characteristics.
Microbe Frequency (n ¼ 47)
Haemophilus inﬂuenzae 38 (81%)
Pseudomonas aeruginosa 12 (26%)
Streptococcus pneumoniae 9 (19%)
Klebsiella pneumoniae 4 (9%)
Staphylococcus aureus 4 (9%)
Klebsiella ozaenae 3 (6%)
Moraxella catarrhalis 3 (6%)
Escherichia coli 2 (4%)
Stenotrophomonas 1 (2%)
Maltophilia 1 (2%)
Morganella morganii 1 (2%)
MAC 1 (2%)
D.P. Steinfort et al.576not isolated from sputum. Serological studies for human
T-cell lymphotropic virus type 1(HTLV-1) were performed for
25 patients; 18 (72%) were positive.Microbiology
One or more sputum cultures, from both current and all
prior admissions, were available for 57 patients. A wide
variety of pathogenic organisms were found (Table 3).
Twenty-six patients (47%) had a single isolate, 12 had two
pathogens isolated, and nine had three or more pathogens
isolated from sputa.Spirometry
Respiratory function tests were tested in 13 patients. All
demonstrated mixed ventilatory defects. Overall, forced
expiratory volume in 1 s (FEV1) was 36711.0% (mean7
standard deviation) of that predicted and forced vital
capacity (FVC) was 47711.7% of that predicted.Discussion
Bronchiectasis prevalence has received little attention in
recent decades. As a result the prevalence in adults in
Australia is not certain. Among our adult cohort, bronch-
iectasis occurs at a young age (mean 42 years) with patients
demonstrating signiﬁcant ventilatory impairment, based on
spirometry. Our cohort demonstrates a high level of
morbidity, as indicated by the number of bed days required
for in-patient care of the condition, and a remarkably high
number of deaths during the study period; twice that
previously reported.2 It is clear that it remains a major cost
burden.
Prominent differences in aetiology between our cohort
and previously published data can be observed.7,9 The
majority of patients appear to have developed disease as a
result of recurrent respiratory infection. In contrast, a
recent cohort from a tertiary teaching hospital in a major
Australian city7 noted a rate of idiopathic bronchiectasis of
74% compared with 18% in our cohort. Although rates of
smoking were roughly twice that among the general
Australian population10 prevalence was similar to that
previously reported in indigenous groups11 and appears very
unlikely to be a signiﬁcant factor in the high rate of
bronchiectasis.
Other noted differences between our cohort and previous
published cohorts of bronchiectasis in adults include age and
indigenous ethnicity. In the single previously published
Australian study the mean age was 56714 years.7 Other
studies have reported mean ages of 577168 and 537159
compared to our mean 42715 years.
The vast majority of our patients were indigenous (97%).
Bronchiectasis has previously been noted to occur at a far
higher rate in Australian indigenous populations in compar-
ison to non-indigenous populations.12 The prevalence among
indigenous Australian children has been recorded as being as
high as 1.5%.5 The rate of early childhood respiratory
infections in Australian indigenous populations has been
recorded at 4.6–9.9 times that of non-indigenous popula-
tions.12 A strong association between bronchiectasis, and
severe and recurrent pneumonia episodes in infancy and
childhood has been described among indigenous children
both in Australia13 and Alaska.14
HTLV-1 is endemic in all continents15 though Australia has
one of the lowest seroprevalence rates world-wide; one in
100,000.16 A statistical association between HTLV-1 and
bronchiectasis in the Central Australian indigenous popula-
tion has previously been reported.17 Our result (72%
seropositivity) is much higher than previously reported
seroprevalence rates in this region (13.9%)18 and are
therefore consistent with this observation. While HTLV-1 is
rarely associated with speciﬁc lymphoproliferative and
neurological disorders, less speciﬁc adverse health effects
are suspected as a result of immune dysregulation.19,20
Infection may predispose patients to recurrent or persistent
respiratory infection,21,22 thereby increasing the likelihood
of progression to bronchiectasis. Indeed, high rates of sub-
clinical bronchiectasis have been reported among asympto-
matic HTLV-1 carriers.23
Microbiological patterns are similar among our cohort to
those recorded in previous studies24 with Haemophilus
inﬂuenzae and Pseudomonas aeruginosa the commonest
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Bronchiectasis in Central Australia 577isolates. The rate of infection with Mycobacterium avium
complex (MAC) is low, however, this is consistent with
previous literature that reports MAC infection in bronchiec-
tasis patients to be most common in elderly patients,25 and
infrequent among non-CF populations.26Limitations
Not all cases of bronchiectasis were conﬁrmed by HRCT.
However, the ACCP Guidelines paper on bronchiectasis27
indicates that in those with characteristic CXR changes of
bronchiectasis, HRCT is unnecessary. We therefore feel
these subjects warrant inclusion in our report.
Though the unique geographic position of Alice Springs
means our cohort is highly representative of the burden of
bronchiectasis among the local population, we identify a
number of limitations to our report. A selection bias is
present, favouring those with severe disease who are more
likely to have required in-patient care during the study
period. As well, the retrospective nature of the report and
the non-uniform approach to diagnosis of bronchiectasis and
subsequent investigation limit the strength of the associa-
tions reported.
However, we feel the reported ﬁndings of young age,
aetiology, high morbidity, and indigenous ethnicity, as well
as the association with HTLV-1, are well supported by our
data. While the pathophysiological mechanisms underlying
the potential association between bronchiectasis and HTLV-1
infection remain to be determined, it is conceivable that
HTLV-1 may adversely affect local immunity, predisposing to
recurrent respiratory tract infections and subsequent
bronchiectasis.
Only 21% of subjects had undertaken spirometry. While
values compare poorly with previously published cohorts,7,9
it is not possible to make any ﬁrm conclusions regarding
severity of ventilatory defects among our cohort.
It is also difﬁcult to identify and quantify confounding
factors in our cohort, particularly the well-documented
social and economic disadvantage suffered by indigenous
Australians28 and their role in risk factor exposure, and the
development of bronchiectasis.Conclusion
Bronchiectasis remains a signiﬁcant cause of morbidity and
mortality in Central Australia, almost exclusively among
indigenous populations. Clinical features, most notably age,
but also aetiology differs notably from other published
cohorts. This appears to be the result of sociodemographic
factors peculiar to Central Australia. Recurrent respiratory
infection is the major cause of bronchiectasis in indigenous
patients.
Factors over-represented in the cohort include indigenous
ethnicity, HTLV-1 positivity and childhood in a remote
region. Future prospective studies are required to ascertain
the prevalence of bronchiectasis and to conﬁrm the
signiﬁcance of above-described associations, as well as to
establish the role, and mechanism, of HTLV-1 in disease
pathogenesis.Conﬂict of interest statement
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